Short Interest in Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Drops By 34.5%

Posted by George Bondi on Jul 3rd, 2026

Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO – Get Free Report) saw a large decrease in short interest during the month of June. As of June 15th, there was short interest totaling 5,347,606 shares, a decrease of 34.5% from the May 31st total of 8,160,044 shares. Based on an average daily volume of 3,448,314 shares, the short-interest ratio is presently 1.6 days. Currently, 3.6% of the company’s stock are short sold.

Hedge Funds Weigh In On Mereo BioPharma Group

Several large investors have recently bought and sold shares of MREO. 683 Capital Management LLC grew its holdings in shares of Mereo BioPharma Group by 208.2% during the fourth quarter. 683 Capital Management LLC now owns 15,025,000 shares of the company’s stock worth $6,261,000 after purchasing an additional 10,150,000 shares during the last quarter. EcoR1 Capital LLC lifted its holdings in shares of Mereo BioPharma Group by 70.2% in the 1st quarter. EcoR1 Capital LLC now owns 13,368,855 shares of the company’s stock valued at $4,412,000 after purchasing an additional 5,512,389 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Mereo BioPharma Group by 32,048.5% in the 1st quarter. Bank of America Corp DE now owns 8,195,287 shares of the company’s stock valued at $2,704,000 after purchasing an additional 8,169,795 shares during the last quarter. Defilade Capital Management L.P. acquired a new stake in shares of Mereo BioPharma Group in the 1st quarter valued at about $2,494,000. Finally, Schonfeld Strategic Advisors LLC boosted its position in shares of Mereo BioPharma Group by 251.5% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 6,090,381 shares of the company’s stock valued at $2,538,000 after purchasing an additional 4,357,657 shares during the period. Institutional investors and hedge funds own 62.83% of the company’s stock.

Mereo BioPharma Group Stock Performance

Mereo BioPharma Group stock remained flat at $0.33 during mid-day trading on Friday. 1,415,639 shares of the company’s stock traded hands, compared to its average volume of 1,982,631. The stock has a market cap of $53.42 million, a PE ratio of -6.69 and a beta of 0.35. Mereo BioPharma Group has a one year low of $0.20 and a one year high of $3.05. The business has a 50-day moving average of $0.29 and a two-hundred day moving average of $0.49.

Mereo BioPharma Group (NASDAQ:MREO – Get Free Report) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.03). As a group, equities analysts expect that Mereo BioPharma Group will post -0.02 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently issued reports on MREO. BTIG Research reaffirmed a “buy” rating and set a $1.00 price objective on shares of Mereo BioPharma Group in a research report on Tuesday, May 12th. Lifesci Capital raised Mereo BioPharma Group to a “hold” rating in a report on Thursday, March 19th. Zacks Research upgraded Mereo BioPharma Group from a “strong sell” rating to a “hold” rating in a research note on Wednesday, June 10th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Mereo BioPharma Group in a report on Monday, March 23rd. Three research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Mereo BioPharma Group has a consensus rating of “Hold” and a consensus target price of $3.25.

Check Out Our Latest Stock Analysis on Mereo BioPharma Group

About Mereo BioPharma Group

(Get Free Report)

Mereo BioPharma Group plc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for rare diseases, oncology and severe respiratory conditions. The company pursues an asset‐centric model, in which it in-licenses or acquires clinical-stage small molecules and monoclonal antibodies with established safety profiles. By concentrating resources on a select number of programs, Mereo aims to accelerate proof-of-concept studies and maximize the potential value of each therapeutic candidate.

Mereo’s pipeline includes investigational therapies for skeletal disorders, such as setrusumab (BPS-804) for osteogenesis imperfecta, and treatments for acute and chronic respiratory diseases.